Details of the Drug

General Information of Drug (ID: DM5IKUF)

• Drug Name: Dihydroergotamine
• Synonyms: Migranal (TN)

Indication

Disease Entry	ICD 11	Status	REF
Cluster headache	8A81.0	Approved	[1]
Migraine	8A80	Approved	[2]
Migraine disorder	N.A.	Approved	[1]

• Therapeutic Class: Antimigraine Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  N02CA01: Dihydroergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA01: Dihydroergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
  N02CA01: Dihydroergotamine
  N02CA: Ergot alkaloids
  N02C: ANTIMIGRAINE PREPARATIONS
  N02: ANALGESICS
  N: NERVOUS SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 583.7
  Logarithm of the Partition Coefficient (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.4-4 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The renal clearance of drug is 0.1 L/h [5]
  Elimination: 6-7% of a single intramuscular dose is excreted in the urine [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 0.7 - 1 hour [6]
  Metabolism: The drug is metabolized via the liver [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0734 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.07% [8]
  Vd: The volume of distribution (Vd) of drug is 800 L [5]
• Chemical Identifiers:
  Formula: C33H37N5O5
  IUPAC Name: (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
  Canonical SMILES: C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
  InChI: InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
  InChIKey: LUZRJRNZXALNLM-JGRZULCMSA-N
• Cross-matching ID:
  PubChem CID: 10531
  ChEBI ID: CHEBI:4562
  CAS Number: 511-12-6
  UNII: 436O5HM03C
  DrugBank ID: DB00320
  TTD ID: D0V3ZA
  VARIDT ID: DR00686
  INTEDE ID: DR0504
  ACDINA ID: D00199
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[9]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[10]

Molecular Expression Atlas of This Drug

• The Studied Disease: Cluster headache
• ICD Disease Classification: 8A81.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dihydroergotamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Dihydroergotamine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[11]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Dihydroergotamine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[11]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Dihydroergotamine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[11]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Dihydroergotamine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[11]
Epinephrine	DM3KJBC	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Epinephrine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[12]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Dihydroergotamine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Dihydroergotamine caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[13]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Buspirone.	Anxiety disorder [6B00-6B0Z]	[14]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Dihydroergotamine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[11]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Dihydroergotamine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Dihydroergotamine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Dihydroergotamine caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[13]
Ephedrine	DMMV0KW	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Ephedrine.	Asthma [CA23]	[12]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[14]
Oritavancin	DM28D05	Moderate	Increased metabolism of Dihydroergotamine caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Dihydroergotamine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Dihydroergotamine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Dihydroergotamine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Dihydroergotamine caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Dihydroergotamine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Dihydroergotamine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[16]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Dihydroergotamine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[11]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Dihydroergotamine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Tucatinib	DMBESUA	Major	Decreased metabolism of Dihydroergotamine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Dihydroergotamine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Pseudoephedrine	DMIVJ0D	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Pseudoephedrine.	Breathing abnormality [MD11]	[12]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Dihydroergotamine caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[13]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Dihydroergotamine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[11]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Dihydroergotamine caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[11]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Levomilnacipran.	Chronic pain [MG30]	[14]
Alfentanil	DMVO0UB	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Alfentanil.	Corneal disease [9A76-9A78]	[14]
Remifentanil	DMZTXCH	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Remifentanil.	Corneal disease [9A76-9A78]	[14]
Dextromethorphan	DMUDJZM	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Dextromethorphan.	Cough [MD12]	[14]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Dihydroergotamine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Pasireotide	DMHM7JS	Moderate	Decreased metabolism of Dihydroergotamine caused by Pasireotide mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Dihydroergotamine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[13]
Aminoglutethimide	DMWFHMZ	Moderate	Increased metabolism of Dihydroergotamine caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[11]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Dihydroergotamine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[11]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Dihydroergotamine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
MK-8228	DMOB58Q	Major	Decreased metabolism of Dihydroergotamine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[13]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Dihydroergotamine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Sertraline.	Depression [6A70-6A7Z]	[14]
Trimipramine	DM1SC8M	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Trimipramine.	Depression [6A70-6A7Z]	[14]
Imipramine	DM2NUH3	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Imipramine.	Depression [6A70-6A7Z]	[14]
Fluoxetine	DM3PD2C	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Fluoxetine.	Depression [6A70-6A7Z]	[14]
Nortriptyline	DM4KDYJ	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Nortriptyline.	Depression [6A70-6A7Z]	[14]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Vilazodone.	Depression [6A70-6A7Z]	[14]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Dihydroergotamine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Paroxetine	DM5PVQE	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Paroxetine.	Depression [6A70-6A7Z]	[14]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Selegiline.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Vortioxetine.	Depression [6A70-6A7Z]	[14]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Duloxetine.	Depression [6A70-6A7Z]	[14]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Isocarboxazid.	Depression [6A70-6A7Z]	[18]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Milnacipran.	Depression [6A70-6A7Z]	[14]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Escitalopram.	Depression [6A70-6A7Z]	[14]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Tranylcypromine.	Depression [6A70-6A7Z]	[18]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Desvenlafaxine.	Depression [6A70-6A7Z]	[14]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Phenelzine.	Depression [6A70-6A7Z]	[18]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Trazodone.	Depression [6A70-6A7Z]	[14]
Amoxapine	DMKITQE	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Amoxapine.	Depression [6A70-6A7Z]	[14]
Mirtazapine	DML53ZJ	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Mirtazapine.	Depression [6A70-6A7Z]	[14]
Protriptyline	DMNHTZI	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Protriptyline.	Depression [6A70-6A7Z]	[14]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Maprotiline.	Depression [6A70-6A7Z]	[14]
Griseofulvin	DMK54YG	Moderate	Increased metabolism of Dihydroergotamine caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[11]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Dihydroergotamine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[19]
LEVONORDEFRIN	DMWDJ0H	Major	Additive hypertensive effects by the combination of Dihydroergotamine and LEVONORDEFRIN.	Discovery agent [N.A.]	[12]
Fenfluramine	DM0762O	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[14]
Primidone	DM0WX6I	Moderate	Increased metabolism of Dihydroergotamine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Dihydroergotamine caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Dihydroergotamine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Dihydroergotamine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Dihydroergotamine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Dihydroergotamine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Dihydroergotamine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Dihydroergotamine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Dihydroergotamine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Mephentermine.	Essential hypertension [BA00]	[12]
Oxymetazoline	DM8ZXT6	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Oxymetazoline.	Eyelid inflammatory disorder [9A02]	[12]
Phenylephrine	DMZHUO5	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Phenylephrine.	Faecal incontinence [ME07]	[12]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Dihydroergotamine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[11]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Dihydroergotamine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Dihydroergotamine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Dihydroergotamine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Dipivefrin	DMH5W0G	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Dipivefrin.	Glaucoma [9C61]	[12]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Dihydroergotamine caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[11]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Dihydroergotamine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Major	Decreased metabolism of Dihydroergotamine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Tetrahydrozoline	DMT57WC	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Tetrahydrozoline.	Herpes simplex infection [1F00]	[12]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Dihydroergotamine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[11]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Dihydroergotamine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[11]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Procarbazine.	Hodgkin lymphoma [2B30]	[18]
MK-1439	DM215WE	Moderate	Increased metabolism of Dihydroergotamine caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Dihydroergotamine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Dihydroergotamine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Dihydroergotamine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Efavirenz	DMC0GSJ	Major	Decreased metabolism of Dihydroergotamine caused by Efavirenz mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Saquinavir	DMG814N	Major	Decreased metabolism of Dihydroergotamine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dihydroergotamine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Dihydroergotamine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Major	Decreased metabolism of Dihydroergotamine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Dihydroergotamine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Ritonavir	DMU764S	Major	Decreased metabolism of Dihydroergotamine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Dihydroergotamine caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Dihydroergotamine caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Amlodipine	DMBDAZV	Moderate	Decreased metabolism of Dihydroergotamine caused by Amlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[13]
Methoxamine	DMF5XQH	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Methoxamine.	Hypertension [BA00-BA04]	[12]
Metaraminol	DMWIX23	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Metaraminol.	Hypotension [BA20-BA21]	[12]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Dihydroergotamine caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[22]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Dihydroergotamine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[11]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Dihydroergotamine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[13]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Dihydroergotamine caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Dihydroergotamine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[11]
Naphazoline	DMJFZDL	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Naphazoline.	Itching [1F28-1G07]	[12]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Dihydroergotamine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[11]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Dihydroergotamine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Dihydroergotamine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[11]
Ceritinib	DMB920Z	Major	Decreased metabolism of Dihydroergotamine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Dihydroergotamine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Dihydroergotamine caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[24]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Dihydroergotamine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Idelalisib	DM602WT	Major	Decreased metabolism of Dihydroergotamine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Dihydroergotamine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Dihydroergotamine caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[11]
LGX818	DMNQXV8	Moderate	Increased metabolism of Dihydroergotamine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dihydroergotamine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Danazol	DML8KTN	Moderate	Decreased metabolism of Dihydroergotamine caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[13]
Exjade	DMHPRWG	Moderate	Increased metabolism of Dihydroergotamine caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[11]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Ozanimod.	Multiple sclerosis [8A40]	[18]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dihydroergotamine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Dihydroergotamine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Dihydroergotamine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Dihydroergotamine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Modafinil	DMYILBE	Moderate	Increased metabolism of Dihydroergotamine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[11]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Dihydroergotamine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[15]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Dihydroergotamine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[13]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Sibutramine.	Obesity [5B80-5B81]	[26]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Dexfenfluramine.	Obesity [5B80-5B81]	[14]
Propylhexedrine	DMTBW2O	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Propylhexedrine.	Obesity [5B80-5B81]	[12]
Phenylpropanolamine	DMTFK3O	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Phenylpropanolamine.	Obesity [5B80-5B81]	[12]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Dihydroergotamine caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[11]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Dihydroergotamine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[13]
Pentazocine	DM1XBHS	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Pentazocine.	Pain [MG30-MG3Z]	[14]
Meperidine	DMX4GND	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Meperidine.	Pain [MG30-MG3Z]	[14]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Safinamide.	Parkinsonism [8A00]	[18]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Rasagiline.	Parkinsonism [8A00]	[18]
Dopamine	DMPGUCF	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Dopamine.	Parkinsonism [8A00]	[12]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dihydroergotamine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[27]
Lanreotide acetate	DMG6ZU4	Moderate	Decreased metabolism of Dihydroergotamine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[13]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Dihydroergotamine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[28]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Dihydroergotamine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[13]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Dihydroergotamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[13]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Dihydroergotamine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[11]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Dihydroergotamine caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[13]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Dihydroergotamine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[11]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Dihydroergotamine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[29]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Dihydroergotamine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[11]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Fentanyl.	Sensation disturbance [MB40]	[14]
Sufentanil	DMU7YEL	Major	Additive serotonergic effects by the combination of Dihydroergotamine and Sufentanil.	Sensation disturbance [MB40]	[14]
Norepinephrine	DMOUC09	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Norepinephrine.	Sepsis [1G40-1G41]	[12]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Dihydroergotamine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dihydroergotamine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[11]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Dihydroergotamine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Armodafinil	DMGB035	Moderate	Increased metabolism of Dihydroergotamine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[11]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Dihydroergotamine caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[11]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Dihydroergotamine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[30]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Dihydroergotamine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Dihydroergotamine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[29]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Dihydroergotamine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[11]
Xylometazoline	DMKV32D	Major	Additive hypertensive effects by the combination of Dihydroergotamine and Xylometazoline.	Vasomotor/allergic rhinitis [CA08]	[12]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Dihydroergotamine caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dihydroergotamine 1 mg tablet	1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Dihydroergotamine FDA Label
• [2] Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75.
• [3] FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension
• [4] BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
• [5] FDA Approved Drug Products: TRUDHESA (dihydroergotamine mesylate) nasal spray
• [6] Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22.
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [9] Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
• [10] CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
• [11] Cerner Multum, Inc. "Australian Product Information.".
• [12] Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
• [13] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
• [14] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
• [15] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
• [16] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [17] He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
• [18] Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
• [19] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
• [20] Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
• [21] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [22] Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
• [23] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [26] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
• [27] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [28] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [29] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [30] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.